{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:21:35Z","timestamp":1793496095274,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"French Parkinson Association"},{"name":"UCB"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"DOI":"10.1038\/s41531-025-00937-w","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T11:12:34Z","timestamp":1745493154000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Improvement of apathy in early Parkinson\u2019s disease"],"prefix":"10.1038","volume":"11","author":[{"given":"A.","family":"Castrioto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Anheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Meoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Klinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Sourd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Pelissier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Lhomm\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bichon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Tranchant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Fraix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Thobois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Krack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"937_CR1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S1474-4422(21)00330-6","volume":"21","author":"D Weintraub","year":"2022","unstructured":"Weintraub, D. et al. The neuropsychiatry of Parkinson\u2019s disease: advances and challenges. Lancet Neurol. 21, 89\u2013102 (2022).","journal-title":"Lancet Neurol."},{"key":"937_CR2","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1002\/mds.26431","volume":"30","author":"D Berg","year":"2015","unstructured":"Berg, D. et al. MDS research criteria for prodromal Parkinson\u2019s disease. Mov. Disord. J. Mov. Disord. Soc. 30, 1600\u20131611 (2015).","journal-title":"Mov. Disord. J. Mov. Disord. Soc."},{"key":"937_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1474-4422(14)70287-X","volume":"14","author":"A Schrag","year":"2015","unstructured":"Schrag, A., Horsfall, L., Walters, K., Noyce, A. & Petersen, I. Prediagnostic presentations of Parkinson\u2019s disease in primary care: a case-control study. Lancet Neurol. 14, 57\u201364 (2015).","journal-title":"Lancet Neurol."},{"key":"937_CR4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1136\/jnnp-2020-324266","volume":"92","author":"H Kazmi","year":"2021","unstructured":"Kazmi, H. et al. Late onset depression: dopaminergic deficit and clinical features of prodromal Parkinson\u2019s disease: a cross-sectional study. J. Neurol. Neurosurg. Psychiatry 92, 158\u2013164 (2021).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"937_CR5","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.neurol.2009.06.003","volume":"165","author":"C Ardouin","year":"2009","unstructured":"Ardouin, C. et al. Assessment of hyper- and hypodopaminergic behaviors in Parkinson\u2019s disease. Rev. Neurol. (Paris) 165, 845\u2013856 (2009).","journal-title":"Rev. Neurol. (Paris)"},{"key":"937_CR6","first-page":"1567","volume":"12","author":"F Sampedro","year":"2022","unstructured":"Sampedro, F., Mart\u00ednez-Horta, S., Mar\u00edn-Lahoz, J., Pagonabarraga, J. & Kulisevsky, J. Apathy Reflects Extra-Striatal Dopaminergic Degeneration in de novo Parkinson\u2019s Disease. J. Park. Dis. 12, 1567\u20131574 (2022).","journal-title":"J. Park. Dis."},{"key":"937_CR7","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1136\/jnnp-2022-330790","volume":"94","author":"H Costello","year":"2023","unstructured":"Costello, H. et al. Longitudinal decline in striatal dopamine transporter binding in Parkinson\u2019s disease: associations with apathy and anhedonia. J. Neurol. Neurosurg. Psychiatry 94, 863\u2013870 (2023).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"937_CR8","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1002\/mds.28722","volume":"36","author":"A Maillet","year":"2021","unstructured":"Maillet, A. et al. Serotonergic and Dopaminergic Lesions Underlying Parkinsonian Neuropsychiatric Signs. Mov. Disord. J. Mov. Disord. Soc. 36, 2888\u20132900 (2021).","journal-title":"Mov. Disord. J. Mov. Disord. Soc."},{"key":"937_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/jnnp-2012-302444","volume":"84","author":"A Castrioto","year":"2013","unstructured":"Castrioto, A. et al. Psychostimulant effect of levodopa: reversing sensitisation is possible. J. Neurol. Neurosurg. Psychiatry 84, 18\u201322 (2013).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"937_CR10","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1002\/mds.27213","volume":"32","author":"A Castrioto","year":"2017","unstructured":"Castrioto, A. et al. Reversing dopaminergic sensitization. Mov. Disord.: J. Mov. Disord. Soc. 32, 1679\u20131683 (2017).","journal-title":"Mov. Disord.: J. Mov. Disord. Soc."},{"key":"937_CR11","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1002\/mds.22843","volume":"24","author":"K Dujardin","year":"2009","unstructured":"Dujardin, K., Sockeel, P., Delliaux, M., Dest\u00e9e, A. & Defebvre, L. Apathy may herald cognitive decline and dementia in Parkinson\u2019s disease. Mov. Disord.: J. Mov. Disord. Soc. 24, 2391\u20132397 (2009).","journal-title":"Mov. Disord.: J. Mov. Disord. Soc."},{"key":"937_CR12","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s00415-019-09538-z","volume":"267","author":"GP Martin","year":"2020","unstructured":"Martin, G. P., McDonald, K. R., Allsop, D., Diggle, P. J. & Leroi, I. Apathy as a behavioural marker of cognitive impairment in Parkinson\u2019s disease: a longitudinal analysis. J. Neurol. 267, 214\u2013227 (2020).","journal-title":"J. Neurol."},{"key":"937_CR13","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1093\/brain\/awad324","volume":"147","author":"M B\u00e9reau","year":"2024","unstructured":"B\u00e9reau, M. et al. Motivational and cognitive predictors of apathy after subthalamic nucleus stimulation in Parkinson\u2019s disease. Brain J. Neurol. 147, 472\u2013485 (2024).","journal-title":"Brain J. Neurol."},{"key":"937_CR14","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1136\/jnnp.2008.170043","volume":"80","author":"KF Pedersen","year":"2009","unstructured":"Pedersen, K. F., Alves, G., Aarsland, D. & Larsen, J. P. Occurrence and risk factors for apathy in Parkinson disease: a 4-year prospective longitudinal study. J. Neurol. Neurosurg. Psychiatry 80, 1279\u20131282 (2009).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"937_CR15","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.neurol.2012.05.003","volume":"168","author":"R Levy","year":"2012","unstructured":"Levy, R. Apathy: a pathology of goal-directed behaviour: a new concept of the clinic and pathophysiology of apathy. Rev. Neurol. (Paris) 168, 585\u2013597 (2012).","journal-title":"Rev. Neurol. (Paris)"},{"key":"937_CR16","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1155\/2013\/851890","volume":"27","author":"G Santangelo","year":"2013","unstructured":"Santangelo, G. et al. Apathy in Parkinson\u2019s disease: diagnosis, neuropsychological correlates, pathophysiology and treatment. Behav. Neurol. 27, 501\u2013513 (2013).","journal-title":"Behav. Neurol."},{"key":"937_CR17","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S1474-4422(15)00019-8","volume":"14","author":"J Pagonabarraga","year":"2015","unstructured":"Pagonabarraga, J., Kulisevsky, J., Strafella, A. P. & Krack, P. Apathy in Parkinson\u2019s disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol. 14, 518\u2013531 (2015).","journal-title":"Lancet Neurol."},{"key":"937_CR18","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1136\/jnnp-2018-318265","volume":"90","author":"C Le Heron","year":"2019","unstructured":"Le Heron, C., Holroyd, C. B., Salamone, J. & Husain, M. Brain mechanisms underlying apathy. J. Neurol. Neurosurg. Psychiatry 90, 302\u2013312 (2019).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"937_CR19","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/mds.26587","volume":"31","author":"A Castrioto","year":"2016","unstructured":"Castrioto, A., Thobois, S., Carnicella, S., Maillet, A. & Krack, P. Emotional manifestations of PD: Neurobiological basis. Mov. Disord. J. Mov. Disord. Soc. 31, 1103\u20131113 (2016).","journal-title":"Mov. Disord. J. Mov. Disord. Soc."},{"key":"937_CR20","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1093\/brain\/awq032","volume":"133","author":"S Thobois","year":"2010","unstructured":"Thobois, S. et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson\u2019s disease: predictors and underlying mesolimbic denervation. Brain J. Neurol. 133, 1111\u20131127 (2010).","journal-title":"Brain J. Neurol."},{"key":"937_CR21","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1093\/brain\/aws078","volume":"135","author":"E Lhomm\u00e9e","year":"2012","unstructured":"Lhomm\u00e9e, E. et al. Subthalamic stimulation in Parkinson\u2019s disease: restoring the balance of motivated behaviours. Brain J. Neurol. 135, 1463\u20131477 (2012).","journal-title":"Brain J. Neurol."},{"key":"937_CR22","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1093\/brain\/awt067","volume":"136","author":"S Thobois","year":"2013","unstructured":"Thobois, S. et al. Parkinsonian apathy responds to dopaminergic stimulation of D2\/D3 receptors with piribedil. Brain J. Neurol. 136, 1568\u20131577 (2013).","journal-title":"Brain J. Neurol."},{"key":"937_CR23","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/mds.27602","volume":"34","author":"K Seppi","year":"2019","unstructured":"Seppi, K. et al. Update on treatments for nonmotor symptoms of Parkinson\u2019s disease-an evidence-based medicine review. Mov. Disord. J. Mov. Disord. Soc. 34, 180\u2013198 (2019).","journal-title":"Mov. Disord. J. Mov. Disord. Soc."},{"key":"937_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41531-020-00142-x","volume":"6","author":"A Castrioto","year":"2020","unstructured":"Castrioto, A. et al. A randomized controlled double-blind study of rotigotine on neuropsychiatric symptoms in de novo PD. npj Park. Dis. 6, 41 (2020).","journal-title":"npj Park. Dis."},{"key":"937_CR25","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.3390\/cells12121599","volume":"12","author":"M B\u00e9reau","year":"2023","unstructured":"B\u00e9reau, M. et al. Apathy in Parkinson\u2019s Disease: Clinical Patterns and Neurobiological Basis. Cells 12, 1599 (2023).","journal-title":"Cells"},{"key":"937_CR26","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1093\/brain\/awh445","volume":"128","author":"P Remy","year":"2005","unstructured":"Remy, P., Doder, M., Lees, A., Turjanski, N. & Brooks, D. Depression in Parkinson\u2019s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain J. Neurol. 128, 1314\u20131322 (2005).","journal-title":"Brain J. Neurol."},{"key":"937_CR27","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1002\/mds.27793","volume":"34","author":"S Prange","year":"2019","unstructured":"Prange, S. et al. Early limbic microstructural alterations in apathy and depression in de novo Parkinson\u2019s disease. Mov. Disord. J. Mov. Disord. Soc. 34, 1644\u20131654 (2019).","journal-title":"Mov. Disord. J. Mov. Disord. Soc."},{"key":"937_CR28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/mdc3.13587","volume":"10","author":"RJ Piers","year":"2023","unstructured":"Piers, R. J., Farchione, T. J., Wong, B., Rosellini, A. J. & Cronin-Golomb, A. Telehealth Transdiagnostic Cognitive Behavioral Therapy for Depression in Parkinson\u2019s Disease: A Pilot Randomized Controlled Trial. Mov. Disord. Clin. Pract. 10, 79\u201385 (2023).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"937_CR29","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1177\/0145445519838828","volume":"44","author":"GO Reynolds","year":"2020","unstructured":"Reynolds, G. O., Saint-Hilaire, M., Thomas, C. A., Barlow, D. H. & Cronin-Golomb, A. Cognitive-Behavioral Therapy for Anxiety in Parkinson\u2019s Disease. Behav. Modif. 44, 552\u2013579 (2020).","journal-title":"Behav. Modif."},{"key":"937_CR30","first-page":"2820257","volume":"2024","author":"O Plant","year":"2024","unstructured":"Plant, O. et al. A Cognitive-Behavioral Model of Apathy in Parkinson\u2019s Disease. Park. Dis. 2024, 2820257 (2024).","journal-title":"Park. Dis."},{"key":"937_CR31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.parkreldis.2015.12.004","volume":"23","author":"N Wee","year":"2016","unstructured":"Wee, N. et al. Baseline predictors of worsening apathy in Parkinson\u2019s disease: A prospective longitudinal study. Parkinsonism Relat. Disord. 23, 95\u201398 (2016).","journal-title":"Parkinsonism Relat. Disord."},{"key":"937_CR32","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3390\/brainsci10020078","volume":"10","author":"JK Dlay","year":"2020","unstructured":"Dlay, J. K. et al. Progression of Neuropsychiatric Symptoms over Time in an Incident Parkinson\u2019s Disease Cohort (ICICLE-PD). Brain Sci. 10, 78 (2020).","journal-title":"Brain Sci."},{"key":"937_CR33","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/jnnp-2012-303419","volume":"84","author":"R Erro","year":"2013","unstructured":"Erro, R. et al. Non-motor symptoms in early Parkinson\u2019s disease: a 2-year follow-up study on previously untreated patients. J. Neurol. Neurosurg. Psychiatry 84, 14\u201317 (2013).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"937_CR34","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.parkreldis.2016.04.026","volume":"28","author":"R Erro","year":"2016","unstructured":"Erro, R. et al. Clinical clusters and dopaminergic dysfunction in de-novo Parkinson disease. Parkinsonism Relat. Disord. 28, 137\u2013140 (2016).","journal-title":"Parkinsonism Relat. Disord."},{"key":"937_CR35","doi-asserted-by":"publisher","first-page":"620762","DOI":"10.3389\/fnagi.2020.620762","volume":"12","author":"R Ou","year":"2020","unstructured":"Ou, R. et al. Evolution of Apathy in Early Parkinson\u2019s Disease: A 4-Years Prospective Cohort Study. Front. Aging Neurosci. 12, 620762 (2020).","journal-title":"Front. Aging Neurosci."},{"key":"937_CR36","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/acn3.51022","volume":"7","author":"D Weintraub","year":"2020","unstructured":"Weintraub, D. et al. Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. Ann. Clin. Transl. Neurol. 7, 449\u2013461 (2020).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"937_CR37","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/mds.26208","volume":"30","author":"MGHE den Brok","year":"2015","unstructured":"den Brok, M. G. H. E. et al. Apathy in Parkinson\u2019s disease: A systematic review and meta-analysis. Mov. Disord. J. Mov. Disord. Soc. 30, 759\u2013769 (2015).","journal-title":"Mov. Disord. J. Mov. Disord. Soc."},{"key":"937_CR38","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s40266-022-00942-1","volume":"39","author":"S Prange","year":"2022","unstructured":"Prange, S., Klinger, H., Laurencin, C., Danaila, T. & Thobois, S. Depression in Patients with Parkinson\u2019s Disease: Current Understanding of its Neurobiology and Implications for Treatment. Drugs Aging 39, 417\u2013439 (2022).","journal-title":"Drugs Aging"},{"key":"937_CR39","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/mdc3.13127","volume":"8","author":"GML Eglit","year":"2021","unstructured":"Eglit, G. M. L. et al. Delineation of Apathy Subgroups in Parkinson\u2019s Disease: Differences in Clinical Presentation, Functional Ability, Health-related Quality of Life, and Caregiver Burden. Mov. Disord. Clin. Pract. 8, 92\u201399 (2021).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"937_CR40","doi-asserted-by":"publisher","first-page":"e0169938","DOI":"10.1371\/journal.pone.0169938","volume":"12","author":"Y-S Ang","year":"2017","unstructured":"Ang, Y.-S., Lockwood, P., Apps, M. A. J., Muhammed, K. & Husain, M. Distinct Subtypes of Apathy Revealed by the Apathy Motivation Index. PLOS ONE 12, e0169938 (2017).","journal-title":"PLOS ONE"},{"key":"937_CR41","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1002\/mds.26058","volume":"29","author":"K Dujardin","year":"2014","unstructured":"Dujardin, K. et al. Apathy in untreated early-stage Parkinson disease: relationship with other non-motor symptoms. Mov. Disord.: J. Mov. Disord. Soc. 29, 1796\u20131801 (2014).","journal-title":"Mov. Disord.: J. Mov. Disord. Soc."},{"key":"937_CR42","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/archneurol.2010.65","volume":"67","author":"D Weintraub","year":"2010","unstructured":"Weintraub, D. et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch. Neurol. 67, 589\u2013595 (2010).","journal-title":"Arch. Neurol."},{"key":"937_CR43","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/mds.26016","volume":"30","author":"D Weintraub","year":"2015","unstructured":"Weintraub, D., David, A. S., Evans, A. H., Grant, J. E. & Stacy, M. Clinical spectrum of impulse control disorders in Parkinson\u2019s disease. Mov. Disord.: J. Mov. Disord. Soc. 30, 121\u2013127 (2015).","journal-title":"Mov. Disord.: J. Mov. Disord. Soc."},{"key":"937_CR44","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1002\/mds.26170","volume":"30","author":"D Weintraub","year":"2015","unstructured":"Weintraub, D. et al. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson\u2019s disease. Mov. Disord.: J. Mov. Disord. Soc. 30, 919\u2013927 (2015).","journal-title":"Mov. Disord.: J. Mov. Disord. Soc."},{"key":"937_CR45","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1007\/s00415-024-12233-3","volume":"271","author":"G Maggi","year":"2024","unstructured":"Maggi, G., Loayza, F., Vitale, C., Santangelo, G. & Obeso, I. Anatomical correlates of apathy and impulsivity co-occurrence in early Parkinson\u2019s disease. J. Neurol. 271, 2798\u20132809 (2024).","journal-title":"J. Neurol."},{"key":"937_CR46","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41531-023-00596-9","volume":"9","author":"H Theis","year":"2023","unstructured":"Theis, H. et al. Impulsive-compulsive behaviour in early Parkinson\u2019s disease is determined by apathy and dopamine receptor D3 polymorphism. npj Park. Dis. 9, 154 (2023).","journal-title":"npj Park. Dis."},{"key":"937_CR47","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1002\/mds.26248","volume":"30","author":"T Simuni","year":"2015","unstructured":"Simuni, T. et al. Correlates of excessive daytime sleepiness in de novo Parkinson\u2019s disease: A case control study. Mov. Disord.: J. Mov. Disord. Soc. 30, 1371\u20131381 (2015).","journal-title":"Mov. Disord.: J. Mov. Disord. Soc."},{"key":"937_CR48","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1212\/WNL.59.3.408","volume":"59","author":"T Witjas","year":"2002","unstructured":"Witjas, T. et al. Nonmotor fluctuations in Parkinson\u2019s disease: frequent and disabling. Neurology 59, 408\u2013413 (2002).","journal-title":"Neurology"},{"key":"937_CR49","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1002\/mds.26731","volume":"31","author":"R Mart\u00ednez-Fern\u00e1ndez","year":"2016","unstructured":"Mart\u00ednez-Fern\u00e1ndez, R., Schmitt, E., Martinez-Martin, P. & Krack, P. The hidden sister of motor fluctuations in Parkinson\u2019s disease: A review on nonmotor fluctuations. Mov. Disord. J. Mov. Disord. Soc. 31, 1080\u20131094 (2016).","journal-title":"Mov. Disord. J. Mov. Disord. Soc."},{"key":"937_CR50","first-page":"323","volume":"13","author":"A Alonso-Canovas","year":"2023","unstructured":"Alonso-Canovas, A. et al. The Early Treatment Phase in Parkinson\u2019s Disease: Not a Honeymoon for All, Not a Honeymoon at All?. J. Park. Dis. 13, 323\u2013328 (2023).","journal-title":"J. Park. Dis."},{"key":"937_CR51","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/gps.5415","volume":"36","author":"C Pennington","year":"2021","unstructured":"Pennington, C., Duncan, G. & Ritchie, C. Altered awareness of cognitive and neuropsychiatric symptoms in Parkinson\u2019s disease and Dementia with Lewy Bodies: A systematic review. Int. J. Geriatr. Psychiatry 36, 15\u201330 (2021).","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"937_CR52","doi-asserted-by":"publisher","first-page":"114331","DOI":"10.1016\/j.psychres.2021.114331","volume":"307","author":"JJ Zakrzewski","year":"2022","unstructured":"Zakrzewski, J. J. et al. Subjective cognitive complaints and objective cognitive impairment in hoarding disorder. Psychiatry Res. 307, 114331 (2022).","journal-title":"Psychiatry Res."},{"key":"937_CR53","first-page":"1329","volume":"126","author":"RP Barbosa","year":"2019","unstructured":"Barbosa, R. P. et al. Cognitive complaints in Parkinson\u2019s disease patients: from subjective cognitive complaints to dementia and affective disorders. J. Neural Transm. Vienna Austria 1996 126, 1329\u20131335 (2019).","journal-title":"J. Neural Transm. Vienna Austria 1996"},{"key":"937_CR54","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/mds.870100316","volume":"10","author":"RA Maricle","year":"1995","unstructured":"Maricle, R. A., Nutt, J. G. & Carter, J. H. Mood and anxiety fluctuation in Parkinson\u2019s disease associated with levodopa infusion: preliminary findings. Mov. Disord.: J. Mov. Disord. Soc. 10, 329\u2013332 (1995).","journal-title":"Mov. Disord.: J. Mov. Disord. Soc."},{"key":"937_CR55","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz, C. G. et al. Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord.: J. Mov. Disord. Soc. 23, 2129\u20132170 (2008).","journal-title":"Mov. Disord.: J. Mov. Disord. Soc."},{"key":"937_CR56","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1176\/jnp.4.2.134","volume":"4","author":"SE Starkstein","year":"1992","unstructured":"Starkstein, S. E. et al. Reliability, validity, and clinical correlates of apathy in Parkinson\u2019s disease. J. Neuropsychiatry Clin. Neurosci. 4, 134\u2013139 (1992).","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"937_CR57","doi-asserted-by":"crossref","unstructured":"Beck, A. T., Steer, R. A. & Brown, G. K. Manual for the Beck Depression Inventory-II. (Psychological Corporation, San Antonio, TX, 1996).","DOI":"10.1037\/t00742-000"},{"key":"937_CR58","unstructured":"Spielberger, C. D., Gorsuch, R. L., Lushene, R., Vagg, P. R. & Jacobs, G. A. Manual for the State-Trait Anxiety Inventory. (Consulting Psychologists Press, Palo Alto, CA, 1983)."},{"key":"937_CR59","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/mds.26223","volume":"30","author":"I Rieu","year":"2015","unstructured":"Rieu, I. et al. International validation of a behavioral scale in Parkinson\u2019s disease without dementia. Mov. Disord. J. Mov. Disord. Soc. 30, 705\u2013713 (2015).","journal-title":"Mov. Disord. J. Mov. Disord. Soc."},{"key":"937_CR60","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.parkreldis.2004.07.007","volume":"11","author":"RG Brown","year":"2005","unstructured":"Brown, R. G., Dittner, A., Findley, L. & Wessely, S. C. The Parkinson fatigue scale. Parkinsonism Relat. Disord. 11, 49\u201355 (2005).","journal-title":"Parkinsonism Relat. Disord."},{"key":"937_CR61","unstructured":"Mattis, S. Dementia Rating Scale. Professional Manual. (Psychological Assessment Resources, Odessa, 1988)."},{"key":"937_CR62","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1212\/WNL.55.11.1621","volume":"55","author":"B Dubois","year":"2000","unstructured":"Dubois, B., Slachevsky, A., Litvan, I. & Pillon, B. The FAB: a Frontal Assessment Battery at bedside. Neurology 55, 1621\u20131626 (2000).","journal-title":"Neurology"},{"key":"937_CR63","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/ageing\/26.5.353","volume":"26","author":"C Jenkinson","year":"1997","unstructured":"Jenkinson, C., Fitzpatrick, R., Peto, V., Greenhall, R. & Hyman, N. The Parkinson\u2019s Disease Questionnaire (PDQ-39): development and validation of a Parkinson\u2019s disease summary index score. Age Ageing 26, 353\u2013357 (1997).","journal-title":"Age Ageing"},{"key":"937_CR64","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/mds.29410","volume":"38","author":"ST Jost","year":"2023","unstructured":"Jost, S. T., et al. Levodopa Dose Equivalency in Parkinson\u2019s Disease: Updated Systematic Review and Proposals. Mov. Disord. J. Mov. Disord. Soc. 38, 1236\u20131252 (2023).","journal-title":"Mov. Disord. J. Mov. Disord. Soc."},{"key":"937_CR65","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1136\/jnnp.2005.075929","volume":"77","author":"P Sockeel","year":"2006","unstructured":"Sockeel, P. et al. The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry 77, 579\u2013584 (2006).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"937_CR66","unstructured":"O\u2019Brien, R. G., Muller, K. E. Applied Analysis of Variance in Behavioral Science. in 297\u2013344 (Marcel Dekker, 1993)."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-00937-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-00937-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-00937-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T23:36:19Z","timestamp":1745537779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-00937-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["937"],"URL":"https:\/\/doi.org\/10.1038\/s41531-025-00937-w","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"12 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.C. received a research grant from Medtronic (to the institution), reimbusement for scientific meetings from ABBVIE, honoraria for lectures from MDS and ABBVIE, M.A.: Abbvie, Merz, Aguettant, Biogen Pharmaceuticals, Ipsen Pharma, Linde, Ever Pharma, Medtronic. S.M. received research grant support from Medtronic, Newronika, Grenoble Alpes University, Huntington\u2019s Disease Network. V.F.: Consultancy fees from AbbVie France, Honorarium from MEDTRONIC. C.T.: AbbVie, IPSEN, Lynde. E.M. is an associated editor of npj Parkinson \u0301s Disease. E.M. has received honoraria from Medtronic for consulting services. She has also received restricted research grants from the Grenoble Alpes University, France Parkinson, IPSEN and Abbott. S.T. received grant from ANR, Neuratris, Boston Scientific, personal fees for conferences from Merz, Aguettant, NHC, for board\/consulting from ABBVIE, Medtronic, Boston Scientific, for meetings from MDS and ABBVIE. P.K.: reports research or educational grants from Swiss National Science Foundation, ROGER DE SPOELBERCH Foundation, Fondation Louis-Jeantet, Carigest, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, France Parkinson, Edmond Safra Philantropic Foundation, Bertarelli Foundation, Annemarie Opprecht Foundation, Parkinson Schweiz, Michael J Fox Foundation, Aleva Neurotherapeutics, Boston Scientific, Medtronic, St. Jude Medical, GE Healthcare, Idorsia, UCB, all paid to employing institutions; lecturing fees to employing institution from Boston Scientific, Bial, Advisis; travel expenses to scientific meetings from Boston Scientific, Zambon, Abbvie, Merz Pharma (Schweiz) AG. E.S., H.K., E.L., A.B., D.S., P.P.: declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"89"}}